Study S001522

Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02055014
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 72
Start: 2013-07
Primary completion: 2017-03
Lead sponsor: Sandwell & West Birmingham Hospitals NHS Trust
Conditions: Type 2 Diabetes; Obesity; Diabesity
Interventions: DRUG:Liraglutide; DEVICE:Duodenal-jejunal bypass liner - Endobarrier device
Results posted: FALSE
Secondary identifiers: REGISTRY:ISRCTN00151053; EUDRACT_NUMBER:2012-004988-42

Registered primary outcomes

Glycated haemoglobin (HbA1c) [24 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0038087	Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes Piya Sen Gupta, Diabetes	2018	Randomized trial	DOI	cites ISRCTN:ISRCTN00151053
R0048567	OC-001 Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the uk’s first nhs endobarrier service for diabesity Marina Anderson, Oral Presentations	2017	Randomized trial	DOI	cites ISRCTN:ISRCTN00151053